Osteoporosis in treated adult coeliac disease

X A McFarlane, A K Bhalla, D E Reeves, L M Morgan, D A F Robertson

Abstract
Forty five women and 10 men with coeliac disease diagnosed in adult life, who were already on a gluten free diet, had serial bone mineral density measurements at the lumbar spine and femoral neck over 12 months. Osteoporosis, defined as a bone mineral density (BMD) ≤2 SD below the normal peak bone mass was found in 50% of male and 47% of female coeliac patients. Patients with a BMD ≤2 SD below age and sex matched normal subjects, had a significantly lower body mass index (21.3 kg.m⁻² compared with 25.2 kg.m⁻², p<0.02 Wilcoxon rank sum test) and lower average daily calcium intake (860 mg/day compared with 1054 mg/day, p<0.05 Wilcoxon rank sum test) than patients with normal bone mineral density. In postmenopausal women with coeliac disease there was a strong correlation between the age at menopause and BMD at both the lumbar spine (r=0.681, p<0.01, Spearman’s rank correlation) and femoral neck (r=0.632, p<0.01). No overall loss of bone was shown over the 12 months of follow up, and relative to the reference population there was a significant improvement in BMD at the lumbar spine in women (p<0.025, paired t test) and at the femoral neck in men (p<0.05, paired t test). There was a significant negative correlation between the annual percentage change in BMD at the lumbar spine and the duration of gluten free diet (r=−0.429, p<0.01, Spearman’s rank correlation), with the largest gain in BMD in patients with most recently diagnosed coeliac disease. Osteoporosis was shown in 47% of patients with treated adult coeliac disease. Recognised risk factors for osteoporosis in the general population including low body mass index, dietary calcium intake, and early menopause are particularly important in coeliac disease. Treatment of coeliac disease with a gluten free diet probably protects against further bone loss, and in the early stages is associated with a gain in bone mineral density.

Keywords: coeliac disease, osteoporosis, gluten free diet.

Osteomalacia, bone pain, pathological fractures, and osteoporosis can occur as presenting features of coeliac disease, particularly where there is florid malabsorption leading to vitamin D deficiency. Patients with coeliac disease now present more often in adult life with mild nutritional deficiencies such as iron or folic acid deficiency, and recent reports suggest that reduced bone mineral density is common at presentation. We therefore studied the prevalence of osteoporosis in asymptomatic adults with treated coeliac disease, and utilised serial bone mineral density measurements to detect any change in bone mineral density over 12 months.

Subjects
Fifty five patients (45 women and 10 men) with coeliac disease diagnosed in adult life (>18 years old at the time of diagnosis) and already established on a gluten free diet were recruited to the study from the gastroenterology outpatients department at the Royal United Hospital, Bath on 24 September 1991 and 21 October 1992. Coeliac disease was defined as small intestinal malabsorption associated with the characteristic small intestinal mucosal lesion together with clinical and histological improvement on a gluten free diet.

The average age of the men was 50.2 years (range 27.0–65.0 years) and that of the women was 51.3 years (range 33.6–69.1 years). With regard to the women, the average age at menarche was 14 years (range 10–20 years; five patients had menarche at age 16 years or older). Five women (no overlap with the delayed menarche group) had a history of an episode of premenopausal amenorrhoea of at least six months. Sixteen women were premenopausal, 11 were perimenopausal, and 18 were postmenopausal (average age at menopause was 46.3 years, range 34 to 57 years, eight patients had had the menopause at age less than 45 years).

Seven patients had been previously treated with oral vitamin D preparations, six had been on glucocorticoids in the past, and five of the women were either on, or had previously been on, hormone replacement therapy for more than 12 months. Fourteen patients (two men) had a history of a serious fracture (rib, clavicle, ankle, forearm, sternum, scaphoid).

The average weight of the women was 61.7 kg (range 35.9–92.7 kg) and that of the men was 74.5 kg (range 55.9–97 kg). The average height of the women was 1.62 m (range 1.40–1.75 m) and that of the men was 1.74 m (range 1.60–1.86 m). The mean times spent on a gluten free diet were 4.25 years (range 0.4–10 years) in men and 9.2 years (range 0.3–40 years) in women.

Methods
A dietary assessment was performed, based on a 10 day weighed record of all food consumed, and the dietary intakes of calcium,
Osteoporosis in treated adult coeliac disease

![Figure 1: Ranked T scores (number of SDs by which individual patients bone mineral density differs from peak bone mass of normal sex matched adults) in 55 patients with adult coeliac disease.](image)

- **T score** is calculated as:
  \[
  T \text{ score} = \frac{\text{patient BMD} - \text{mean BMD of sex matched normals}}{\text{SD of peak BMD of sex matched normals}}
  \]

- **Z score** is calculated as:
  \[
  Z \text{ score} = \frac{\text{patient BMD} - \text{mean BMD of age and sex matched normals}}{\text{SD of BMD of age and sex matched normals}}
  \]

There is a close relationship between low BMD and fracture risk. Some authors consider a T score $<-2$ as sufficient to diagnosis osteoporosis, whereas others define an isolated reduction of T score as osteopaenia, and require in addition, the presence of fragility fracture to diagnose osteoporosis.

The Z score provides an index of the relative risk of fracture compared with that of an individual with Z score of 0. A bone mineral density Z score of $-1$ at the femoral neck suggests a 2.5-fold increase risk of fracture over the patient’s lifetime, and a Z score of $<-2$ implies a 5.2-fold increased risk of fracture.

The Z score is used in this study for the purpose of analysis of risk factors for reduced bone mass, as the Z score eliminates the effects of age and sex by considering each patient’s BMD in relation to the age and sex matched normal population.

The change in BMD (g.cm$^{-2}$.y$^{-1}$) is expressed as the absolute change per year (absolute BMD after 12 months−absolute BMD on entry) and an annual percentage change:

\[
\text{Annual } \% \text{ change} = \frac{100 \times (\text{BMD after } 12 \text{ months} - \text{BMD on entry})}{\text{BMD on entry}}
\]

Any change in BMD in relation to the age and sex matched normal population is detected as a change in the Z score:

\[
\text{Change } = Z \text{ score after } 12 \text{ months} - Z \text{ score on entry to the study.}
\]

All 55 patients were followed for the full 12 months of the study. Two of the patients with the lowest initial Z scores underwent iliac crest bone biopsy after a tetracycline double labelling technique.

The statistical significance of differences between unpaired data was calculated using the Wilcoxon rank sum test. The correlation coefficient was calculated using Spearman’s rank correlation. Ninety-five percent confidence intervals (95% CI) for the difference between paired data were calculated using Student’s t distribution and significance was determined by paired t test.

### Results

Twenty-one women (47%) and five (9%) men had a T score $<-2$ at either the lumbar spine or femoral neck, or at both sites (nine women and two men had T scores $<-2$ at both the lumbar spine and femoral neck). Eight of the patients (six women) with T score $<-2$ had a past history of important bone fracture. Ranked T scores at lumbar spine and femoral neck are shown in Figure 1.

Eleven (20%) patients (nine women, two men) had a Z score $<-2$ at either the lumbar spine or femoral neck, or both, four of whom (all female) had a Z score $<-2$ at both the lumbar spine and femoral neck. Thirteen (24%) patients (10 women, three men) had a Z score $<-1$. Thirty-one (56%) patients (26 women, five men) had a Z score $<-1$ at both the lumbar spine and femoral neck. Comparisons between these three groups of patients are shown in the Table. All patients with a Z score $<-2$ also had T score $<-2$.

There was a close correlation between the BMD (g.cm$^{-2}$) at the lumbar spine and femoral neck (men: $r=+0.782$, $p<0.02$, $n=55$).

- **Table**: Comparison of BMD and T score at lumbar spine and femoral neck among different groups of patients.

- **Figure**: Graph showing the distribution of T scores and Z scores at lumbar spine and femoral neck.
Mean values of biochemical, dietary, and anthropometric results.

<table>
<thead>
<tr>
<th>Z score range</th>
<th>Women/men</th>
<th>Age (y)</th>
<th>Years on gluten free diet</th>
<th>% change in lumbar spine BMDy</th>
<th>% change in femoral neck BMDy</th>
<th>Body mass index (kg.m⁻²)</th>
<th>Intake of calcium (mg/d) (% RNI)</th>
<th>Intake of energy (kcal (%RNI)</th>
<th>Intake of protein (g/d) (% RNI)</th>
<th>Serum calcium (mmol/l) (2.00–2.70)</th>
<th>Serum phosphate (mmol/l) (1.00–1.90)</th>
<th>Mean corpuscular volume (fl)</th>
<th>Mean corpuscular protein mass (g.cm⁻²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z&lt; -2</td>
<td>(n=11)</td>
<td>9.2</td>
<td>48.7</td>
<td>9.1</td>
<td>0.05</td>
<td>21.3</td>
<td>860 (123)*</td>
<td>1.02</td>
<td>70.9</td>
<td>2.37</td>
<td>1.02</td>
<td>89.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Z = -1</td>
<td>(n=31)</td>
<td>10.3</td>
<td>51.9</td>
<td>6.0</td>
<td>2.24</td>
<td>23.1</td>
<td>1105 (158)</td>
<td>1.04</td>
<td>79.6</td>
<td>2.25</td>
<td>1.04</td>
<td>89.6</td>
<td>1.0</td>
</tr>
<tr>
<td>Z = 1</td>
<td></td>
<td>26/5</td>
<td>51.6</td>
<td>9.2</td>
<td>-0.03</td>
<td>25.2</td>
<td>1054 (151)</td>
<td>2.31</td>
<td>75.6</td>
<td>7.3</td>
<td>1.01</td>
<td>90.1</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Significant difference between patients with reduced bone mineral density (BMD) (Z< -2 or Z= -1) and patients with normal bone mineral density (Z> = -1) is denoted by an asterisk (*p<0.05, **p<0.01, ***p<0.001, Wilcoxon rank sum test). RNI=reference nutrient intake, PTH=parathyroid hormone.

women: r=+0.704, p<0.001). The BMD at the lumbar spine (L1–4) in women is shown in Figure 2.

Serial BMD measurements showed an average annual change at the lumbar spine in men of +0.021 g.cm⁻².y⁻¹ (95% CI= 0.009, 0.035 g.cm⁻².y⁻¹) equivalent to a +2.76% change, and in women of +0.003 (95% CI= 0.004, 0.010 g.cm⁻².y⁻¹) equivalent to a +0.25% change. The average annual change at the femoral neck in men was +0.016 g.cm⁻².y⁻¹ (95% CI= 0.016, 0.039 g.cm⁻².y⁻¹) equivalent to a 2.41% change, and in women of +0.000 (95% CI= 0.005, 0.012 g.cm⁻².y⁻¹) equivalent to a 0.66% change.

The change in Z score at the lumbar spine was +0.26 (95% CI= 0.02, 0.56) in men and +0.07 (95% CI= 0.01, 0.14, p=0.025 paired t test) in women. The change in Z score at the femoral neck was +0.25 (95% CI= 0.04, 0.46, p<0.05 paired t test) in men and +0.08 (95% CI= 0.02, 0.18) in women.

The average intakes of calcium, energy, and protein were above the reference nutrient intake for each nutrient (2 SDs above the intake for a nutrient that would be adequate for 50% of the normal population). The United Kingdom reference nutrient intake (RNI) for calcium is 700 mg/day for adults.¹¹

The mean plasma concentrations of calcium, phosphate, total alkaline phosphatase, 25 hydroxyvitamin D, red cell folate, and 24 hour urine calcium were in the normal range (Table), however, some patients had a minor reduction of calcium or phosphate, or a slight increase in total alkaline phosphatase or IPTh. No patient had a subnormal 25 hydroxyvitamin D value, but levels near the lower limit of the normal range were detected in a few. Bone biopsies showed severe osteoporosis, with marked trabecular thinning, but there was no increase in osteoid thickness or any other histological evidence of osteomalacia in either of the patients who had this investigation.

Compared with patients with a Z score ≥ −1 at both lumbar spine and femoral neck (Table), patients with Z score < −2 at one or both sites had significantly lower average daily calcium intake (860 mg/d compared with 1054 mg/d, p<0.05) and a lower BMI (21.3 kg.m⁻² compared with 25.2 kg.m⁻², p<0.02). There was no significant difference (p=0.10) between these groups in the length of time on a gluten free diet, age at diagnosis of coeliac disease, any of the blood or urine biochemical indices, or of other risk factors for osteoporosis (smoking, level of physical activity, use of glucocorticoids, age at menarche in women).

There was no significant difference in Z scores in premenopausal, perimenopausal, or postmenopausal women at either the lumbar spine or femoral neck. In postmenopausal females, however, the age at menopause was significantly correlated with the lumbar spine Z score (r=0.681, p<0.01) and with the femoral neck Z score (r=0.632, p<0.01, Fig 3). Patients with a history of bone fracture had no significant difference in Z score when compared with patients with no history of fracture.

There was no significant correlation between the duration of the GFD and the femoral or lumbar Z score, but there was a negative correlation between the annual percentage change in the BMD at the lumbar spine (women: r=–0.405, p<0.01, men: r=–0.709, p<0.05, Fig 4). Many of the most recently diagnosed patients showed a significant improvement in BMD over the 12 months of the study. The four osteoporotic women who lost bone more rapidly than −2% per annum at the lumbar spine had all undergone the menopause at age 40 years or less.

**Discussion**

Bone mass increases throughout childhood and adolescence²² ²³ to the peak bone mass at about the third decade with a slow decline thereafter in men and premenopausal women²⁴ and a rapid loss of bone mass in women in the early postmenopausal years.²⁵ Peak bone mass and the subsequent decline in bone mass are both determined by genetic and acquired factors. Acquired or environmental factors that may contribute to low bone mass
and fracture risk include dietary calcium intake, the level of physical activity, and in women, oestrogen deprivation. In coeliac disease the villous atrophy and malabsorption are thought to occur at the time of first exposure to gluten – that is, at weaning. Patients in this study were all diagnosed in adult life, after the age at which the maximum rate of gain of bone mass occurs, and a possible explanation for the low BMD seen is that they failed to reach an optimal peak bone mass in early adult life. Forty seven per cent of patients in this study had osteoporosis defined as a bone mineral density 2 SD or more below the mean sex matched peak bone mass.

Reduced bone mineral density occurred in all age ranges, in both sexes, and in many cases was quite profound. Twenty four per cent of patients had $-2<Z$ score $<-1$, and therefore at least a twofold increase in lifetime fracture risk, and $20\%$ of patients had $Z$ score $<-2$, and therefore at least a fivefold increase in lifetime fracture risk.

Postmenopausal patients with coeliac disease who had an early menopause were particularly susceptible to low bone density, and to a rapid loss of bone mass ($>-2\%/\text{year}$) whereas women with an onset of menopause after the age of 50 years seemed to be relatively protected from low bone density, and did not suffer rapid bone loss. It is clear that the protective effect of oestrogens on bone mass remains important in women with coeliac disease.

There was a predominance of females in the study (4:5:1) which is higher than that reported for coeliac disease in general (1:1 to 2:1). This bias in the study population is probably explained by the demanding nature of the study which discouraged men in full time employment from taking part. However, the magnitude of the abnormalities shown seems to be of the same order in men and women. There was a high proportion of perimenopausal and postmenopausal women, but it is unlikely that all of the reduction in BMD is due to menopausal loss. Premenopausal women had a lower (not significant, $p>0.10$) absolute BMD than menopausal women, and some of the patients with the lowest Z scores were premenopausal.

In some individuals, calcium intake was marginal. Bread and cereals contribute approximately 25% of dietary calcium, and unless the individual has an adequate intake of dairy products, a gluten free diet may not provide adequate dietary calcium. In addition, the United Kingdom recommended nutrient intakes for calcium may not be adequate for adults with treated coeliac disease as there is evidence for continued malabsorption of calcium despite a gluten free diet. The correlation of bone mass with dietary calcium intake demonstrated in this study provides evidence to support a recommendation to increase calcium intakes in patients with coeliac disease to levels recommended for adults by the American National Institutes of Health (1000 mg/d for premenopausal women and 1500 mg/d for post menopausal women not treated with oestrogen).

There were no biochemical parameters which predicted osteoporosis in this study, but the clear association with BMI is helpful, and is consistent with the recognised association in the general population. We have shown an overall increase in the BMD Z score over the 12 months of the study at the lumbar spine in women and femoral neck in men which is surprising and requires explanation. The largest gains in Z scores and absolute BMD were detected in the most recently diagnosed patients suggesting that there is a reversible component to the osteopaenia present at the time of diagnosis of coeliac disease, and that this can be improved by treatment with a gluten free diet. The rapid loss of bone in women who had the menopause at age less than 45 years emphasises the continuing skeletal demineralisation and need for active treatment in this group.

Screening for osteoporosis by measuring bone mineral density in adult coeliac disease seems to be worthwhile with a high yield, many patients having reduced bone mineral density.
This has therapeutic potential, and having identified at risk individuals the need for adherence to gluten free diet can be emphasised and advice regarding treatment can be offered, which may include increasing dietary calcium intake or considering hormone replacement treatment in postmenopausal women, in particular those with an early menopause.

This work was supported by a grant from the Coeliac Trust.


